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OBJECTIVES: To investigate whether blood total lysosomal acid lipase activity (BT-LAL) levels are uniquely
associated with the noncirrhotic and cirrhotic stages of nonalcoholic fatty liver disease (NAFLD)
and with protection from NAFLD in metabolically/genetically predisposed subjects and a normal
liver. To clarify which enzyme-carrying circulating cells are involved in reduced BT-LAL of NAFLD.
METHODS: In a cross-sectional study, BT-LAL was measured by a fluorigenic method in patients with NAFLD (n5
118), alcoholic (n5 116), and hepatitis C virus-related disease (n5 49), in 103 controls with normal
liver and in 58 liver transplant recipients. Intracellular platelet and leukocyte LAL was measured in 14
controls and 28 patients with NAFLD.
RESULTS: Compared with controls, (i) BT-LAL and LAL in platelets, but not in leukocytes, were progressively
reduced in noncirrhotic NAFLD and in nonalcoholic steatohepatitis-related cirrhosis; (ii) platelet and
leukocyte counts did not differ in patients with noncirrhotic NAFLD; and (iii) BT-LAL did not differ in
alcoholic and hepatitis C virus noncirrhotic patients. BT-LAL progressively increased in controls with
metabolic syndrome features according to their PNPLA3 rs738409 steatosis-associated variant status
(II vs IM vsMM), and their BT-LALwas higher than that of noncirrhotic NAFLD, only when carriers of the
PNPLA3 unfavorable alleles were considered. Liver transplant recipients with de novo NAFLD
compared with those without de novo NAFLD had lower BT-LAL.
DISCUSSION: LAL in blood and platelets is progressively and uniquely reduced in NAFLD according to disease
severity. High BT-LAL is associated with protection fromNAFLD occurrence in subjects with metabolic
and genetic predisposition. Low LAL in platelets and blood could play a pathogenetic role in NAFLD.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A150, http://links.lww.com/CTG/A151, http://links.lww.com/CTG/A152, http://
links.lww.com/CTG/A153, http://links.lww.com/CTG/A154, http://links.lww.com/CTG/A155, http://links.lww.com/CTG/A156, http://links.lww.com/CTG/A157
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INTRODUCTION
Lysosomal acid lipase is an enzyme that hydrolyzes triglycerides
and cholesteryl esters in several cells including hepatocytes,
Kupffer cells, and bone marrow-derived monocyte-macrophages
(1). The expression of lysosomal acid lipase is constitutive but can
be further regulated by different stimuli. Lysosomal acid lipase
activity (LAL) drives the hydrolysis of lipid droplets, and when
LAL is too low, triglycerides and cholesteryl esters accumulate
inside the lysosomes. In the liver, this accumulation occurs in
both hepatocytes andKupffer cells and favors hepatic steatosis. In
addition, LAL inactivation in hepatocytes and immune cells is
proinflammatory. In fact, the absence of LAL in hepatocytes
causes an increased hepatic infiltration by macrophages (2), and
the knockdown of this enzyme in some immunomodulator cell
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(myeloid derived suppressor cells, macrophages, and Treg and
memory CD81 T cells) induces a lipid metabolic switch, which
favors inflammation in several organs, including the liver (1).
In LAL deficiency, an autosomal recessive disease caused by
mutations in the LIPA gene, which includes severe chronic liver
disease that mimics nonalcoholic fatty liver disease (NAFLD),
blood total LAL (BT-LAL), and intracellular leukocyte LAL is
strongly reduced (3–5). Furthermore, it is known that the liver
disease of LAL deficiency recurs after liver transplantation (LT),
suggesting that the enzymatic deficiency in blood is sufficient to
induce hepatic damage (6).
In addition to leukocytes, platelets have also been recently
shown to contain LAL in healthy controls and BT-LAL is corre-
lated more with LAL in platelets than with LAL in leukocytes (7).
However, although platelets are known to play a role as modu-
lators of liver diseases by nonthrombotic mechanisms that are
incompletely understood (8,9), intracellular LAL in platelets has
never been measured in patients with liver disease.
In the past years, a nongenetically determined reduction of
BT-LALwith a residual enzymatic activity higher than that found
in patients with LAL deficiency has been reported, in separate
studies, regarding patients with noncirrhotic NAFLD (10) and
with cryptogenic cirrhosis (11) compared with controls and in
patients with cryptogenic cirrhosis compared with patients with
cirrhosis of other etiologies (12).
Despite the evidence mentioned above, the association be-
tween reduced activity of BT-LAL and NAFLD throughout all
disease stages is not considered very strong for several reasons.
First of all, it is not knownwhether reduced BT-LAL is peculiar to
NAFLD or it is also present in alcoholic liver disease (ALD),
another condition characterized by hepatic fat accumulation.
Second, it is unclear whether reduced BT-LAL in NAFLD is
simply due to thrombocytopenia, which can be present even at
the precirrhotic stage (10,13) or there is an intrinsic scarce en-
zymatic activity at the blood cell level. In fact, BT-LAL in platelets
has not beenmeasured in patients withNAFLD. Third, regarding
the cirrhotic stage of NAFLD, comparative studies with healthy
controls and with cirrhosis of other etiologies have taken into
consideration patients with cryptogenic cirrhosis and not those
with NASH-related cirrhosis (11,12). In this regard, it should be
emphasized that recent data, although there is no agreement on
the subject, suggest caution in equating the diagnosis of crypto-
genic cirrhosis with that of NASH-related cirrhosis (14–17).
Fourth, although the development of de novoNAFLD after LT in
patients who were not affected by LAL deficiency represents
a further model to test the association of BT-LAL levels with
NAFLD, no data are available on this topic.
Finally, no data are available on BT-LAL in subjects with
normal liver but metabolically and/or genetically predisposed to
NAFLD.
Thus, we compared the following for the first time: (i) BT-LAL
in controls with normal liver and in cirrhotic and noncirrhotic
patients with only one isolated etiology of their chronic liver
disease, namely, alcoholic, hepatitis C virus (HCV), and NAFLD,
selecting patients with NASH-related cirrhosis and excluding
those with cryptogenic cirrhosis; (ii) intracellular LAL in isolated
platelets and leukocytes of subjects with normal liver vs patients
with noncirrhotic NAFLD and with NASH-related cirrhosis; (iii)
BT-LAL values after LT in patients with or without de novo
NAFLD; and (iv) BT-LAL in subjects with noncirrhotic NAFLD
and in those with normal liver but metabolically predisposed to
NAFLD, according to their PNPLA3 rs738409 steatosis-
associated variant status (18).
METHODS
Study population
Consecutive nontransplanted white patients older than 18 years
were enrolled from October 2012 to September 2018 at the De-
partment of Translational and Precision Medicine and the Day
Service of Internal Medicine and Metabolic Diseases of the De-
partment of Internal Medicine of the Sapienza University of
Rome. Patients were enrolled to obtain groups strictly selected for
one single etiology, namely, NAFLD (n 5 118), alcoholic (n 5
116), or HCV (n 5 49), and for disease stage, i.e., cirrhotic vs
noncirrhotic (Supplementary Methods, Supplementary Digital
Content 8, http://links.lww.com/CTG/A157). In particular, cir-
rhosis diagnosis, in general, independently from etiology, was
based on liver biopsy or the presence of at least 2 of the following
features: current or past cirrhosis complications (e.g., ascites,
variceal gastrointestinal bleeding, and hepatic encephalopathy),
the presence of hyperbilirubinemia, hypoalbuminemia, pro-
longed International Normalized Ratio, low platelet count, ir-
regular liver surface at ultrasound/computed tomography,
reduced portal vein flow at ultrasound, liver elastometry, and
gastroesophageal varices at endoscopy. In the absence of patho-
logical diagnosis or overt cirrhosis, individuals with the positivity
of only one of the above-mentioned parameters were excluded
from the study.
Inclusion criteria of noncirrhotic NAFLD and NASH-related
cirrhotic patients were previous or current alcohol consumption
of,20 g/d and the absence of any other etiology of chronic liver
disease. For the diagnosis of noncirrhotic NAFLD, the ultraso-
nographic evidence of liver steatosis at ultrasounds was addi-
tionally requested, defined according to the Hamaguchi criteria
(19), and/or NAFLD diagnosis at histology without cirrhosis and
the absence of cirrhosis diagnosis as mentioned above. Non-
cirrhotic alcoholic or HCV patients with diabetes and/or obesity
were also excluded. Regarding the cirrhotic stage of NAFLD,
patients with cryptogenic cirrhosis were excluded and patients
with NASH-related cirrhosis were only enrolled (Supplementary
Methods, Supplementary Digital Content 8, http://links.lww.
com/CTG/A157).
To investigate whether post-transplant BT-LAL was associ-
ated with de novo NAFLD after LT, 58 stable liver-transplanted
patients without cirrhosis recurrence and with a follow-up of at
least 1 year after operation were consecutively enrolled and
submitted to abdominal ultrasounds and blood sampling for BT-
LAL measurement (Supplementary Methods, Supplementary
Digital Content 8, http://links.lww.com/CTG/A157). HCV-
positive transplanted patients were excluded because HCV vi-
rus can directly cause steatosis even in the post-transplant setting.
Consecutive white adult subjects with normal liver at ultra-
sounds and normal blood liver tests (n 5 103) were enrolled as
controls. These controls were notmatchedwith any patient group
andwere either completely healthy subjects or patients with some
features of metabolic syndrome.
All patients and controls signed the informed consent. The
study was approved by the ethics committee of Policlinico
Umberto I—SapienzaUniversity of Rome (ref. no. 2277/2011 and
4591/2017) and was conducted according to the Declaration of
Helsinki.
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From all patients and controls was recorded a full clinical,
drug, and alcohol consumption history (20), and blood was
sampled for analyses (Supplementary Methods, Supplementary
Digital Content 8, http://links.lww.com/CTG/A157). Non-
cirrhotic NAFLD subjects and controls with at least one feature of
metabolic syndrome were genotyped for the PNPLA3 rs738409
steatosis-associated variant (18).
LAL assays and PNPLA3 genotyping
All enzymatic assays were performed using a fluorimetricmethod
at “Bambino Gesù Hospital” in Rome (Italy), within 1 week from
the day of blood sampling, by a biologist (G.T.) unaware of
clinical and biochemical characteristics of any enrolled subject.
BT-LAL was measured using the fluorimetric method as
reported by Hamilton et al. (Supplementary Methods, Supple-
mentary Digital Content 8, http://links.lww.com/CTG/
A157) (21).
To investigate intracellular LAL, platelets and leukocytes were
isolated as proposed by Dagur and McCoy (22) with small
modifications (Supplementary Methods, Supplementary Digital
Content 8, http://links.lww.com/CTG/A157). Themorphology of
isolated platelets and leukocytes was analyzed by using a FACS-
Calibur cytometer (Becton Dickinson, Mountain View, CA), and
purity was evaluated by immunophenotyping (Supplementary
Methods, Supplementary Digital Content 8, http://links.lww.
com/CTG/A157).
Intracellular LAL in isolated leukocytes and platelets was
measured as reported by Civallero et al. (23) with small mod-
ifications. Enzyme activities were expressed as nmol/mg protein/
h (Supplementary Methods, Supplementary Digital Content 8,
http://links.lww.com/CTG/A157).
Inter- and intra-assay variations of BT-LAL and intracellular
LAL determinations were lower than 5%. The intrapatient vari-
ability was lower than 10%.
PNPLA3 rs738409 was detected using dedicated TaqMan
genotyping (Supplementary Methods, Supplementary Digital
Content 8, http://links.lww.com/CTG/A157).
Statistical analyses
Continuous variables are presented as median (interquartile
range). After the assessment of normality using the
Kolmogorov–Smirnov test, the differences between groups were
evaluated using Mann–Whitney U test or t test according to the
variable normality. Categorical variables were expressed as count
and percentages and compared with the x2 test or Fisher exact
test, as appropriate. Different multivariable binary logistic re-
gression analyses were performed to investigate the association of
BT-LAL with the noncirrhotic and cirrhotic stage of chronic liver
diseases compared with the control group, with the stage of
chronic liver disease of each etiology, and with etiology for each
disease stage. Each multivariable model was adjusted for any
demographic and clinical variable, including the features of
metabolic syndrome and statin use, with a P value , 0.05 at
univariate analyses. To avoid collinearity bias, blood platelet,
leukocyte counts, and serum alanine aminotransferase were not
introduced in themultivariatemodels even if they differed among
groups because they showed correlation with BT-LAL. Compu-
tations were carried out with SPSS software 25.0 for Windows
(SPSS Inc., Chicago, IL).
RESULTS
Demographic, clinical, and biochemical parameters of the study
groups are reported in Table 1. Daily alcohol consumption did
not differ between the noncirrhotic ALD and the alcoholic cir-
rhotic groups, whereas the duration of at-risk alcohol con-
sumption was longer in the alcoholic cirrhotic group. The time
span of HCV infection did not differ between the noncirrhotic
and cirrhotic HCV groups. Diagnosis in patients with non-
cirrhotic NAFLD was obtained in 53 (79%) cases by histology.
BT-LAL did not differ between patients with histological di-
agnosis compared with those who had only ultrasounds and,
among the biopsied subjects, between those with simple steatosis
(n 5 21) compared with those with NASH (n 5 32) (data not
shown).
BT-LAL inpatientswithNAFLDandALDcomparedwith subjects
with normal liver
Because BT-LAL did not differ in patients with noncirrhotic
NAFLD with nonhistological diagnosis and in those with histo-
logically obtained diagnosis of NASH or of simple steatosis (data
not shown), they were all considered as one group. As shown in
Figure 1a, BT-LAL, compared with that of controls (0.94
[0.73–1.76] nmol/spot/hr), did not differ in patients with non-
cirrhotic ALD (1.04 [0.72–1.42] nmol/spot/hr), whereas it pro-
gressively significantly decreased in patients with noncirrhotic
NAFLD (0.64 [0.50–0.91] nmol/spot/hr; P , 0.001), alcoholic
cirrhosis (0.63 [0.46–0.89] nmol/spot/hr; P, 0.001), andNASH-
related cirrhosis (0.48 [0.39–0.69] nmol/spot/hr); P , 0.001).
Platelet count (Figure 1b), comparedwith that of controls, did not
differ in the noncirrhotic ALD and NAFLD groups, whereas it
was significantly reduced in the alcoholic (P, 0.001) andNASH-
related (P, 0.001) cirrhotic groups. Leukocyte count (Figure 1b),
compared with the controls, did not differ in patients with non-
cirrhotic NAFLD, whereas it was significantly higher in patients
with noncirrhotic ALD (P , 0.001) and significantly lower in
patients with alcoholic (P , 0.001) and NASH-related (P ,
0.001) cirrhosis. After correction for the significant intergroup
differences shown in Table 1, at multivariable logistic regression
analyses comparing separately each group with the control group
(Supplementary Table 1, Supplementary Digital Content 3,
http://links.lww.com/CTG/A152), low BT-LAL was in-
dependently associated with noncirrhotic NAFLD (odds ratio
[OR] 0.196; 95% confidence interval [CI]: 0.068–0.568; P 5
0.003), NASH-related cirrhosis (OR 0.003; 95% CI: 0.000–0.058;
P , 0.001), and alcoholic cirrhosis (OR 0.227; 95% CI:
0.070–0.735; P 5 0.013).
We then compared BT-LAL of control subjects with normal
liver and patients with noncirrhotic NAFLD, restricting analyses
only to those with at least one feature of metabolic syndrome in
both groups and also including PNPLA3 genotyping. As shown in
Table 2, the controls compared with the noncirrhotic NAFLD
group had significantly higher BT-LAL and lower leukocyte
count, whereas no difference was present in platelet count. Un-
expectedly, the frequency of the PNPLA3 M allele variant was
significantly higher in the control group than that in the non-
cirrhotic NAFLD group. After correction for the significant in-
tergroup differences shown in Table 2, at multivariable logistic
regression analysis, low BT-LAL was independently associated
with noncirrhotic NAFLD (OR 0.105; 95% CI: 0.022–0.503; P5
0.005) (Supplementary Table 2, Supplementary Digital Content
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Table 1. Demographic, clinical, and biochemical parameters of the study groups
Men,
n (%) Age (yr)
BMI
(kg/m2)
Diabetes,
n (%)
Hypertension,
n (%)
Dyslipidemia,
n (%)
Statins,
n (%)
ALT
(UI/L)
MELD
score
Daily
alcohol
intake
(units)
Years of
at-risk
alcohol
intake
Years
since
HCV
infection
CTRL
(n 5 103)
47 (46) 53
(30–67)
24.4
(22.1–26.6)
6 (6) 30 (29) 56 (54) 26 (25) 16
(12–20)
— — — —
Noncirrhotic
NAFLD
(n 5 67)
36 (54) 53
(41–59)
28.1
(26.0–31.0)
18 (27) 24 (36) 47 (70) 14 (21) 51
(38–83)
— — — —
CIR-NASH
(n 5 51)
34 (67) 66
(58–72)
27.0
(24.7–30.8)
30 (59) 25 (49) 25 (49) 2 (4) 30
(20–43)
13
(10–15)
— — —
Noncirrhotic
ALD (n5 53)
52 (98) 50
(42–58)
24.6
(22.3–26.5)
0 (0) 7 (13) 41 (77) 2 (4) 21
(16–31)
— 13
(10–18)
22
(14–29)
—
CIR-ALD
(n 5 63)
60 (95) 59
(54–64)
26.4
(24.7–28.1)
17 (27) 16 (25) 16 (25) 3 (5) 24
(17–38)
14
(10–17)
12a
(9–16)
31a
(20–40)
—
Noncirrhotic
HCV
(n 5 19)
14 (74) 62
(54–72)
24.6
(22.2–27.0)
0 (0) 9 (47) 9 (47) 0 (0) 33
(25–46)
— — — 23
(15–31)
CIR-HCV
(n 5 30)
19 (63) 63
(55–75)
24.8
(22.9–27.6)
4 (13) 12 (40) 9 (30) 0 (0) 24
(16–64)
10
(8–13)
— — 20
(9–25)
Noncirrhotic
NAFLD vs
CTRL, P
value
0.302 0.652 ,0.001 ,0.001 0.360 0.040 0.514 ,0.001 NA NA NA NA
CIR-NASH vs
CTRL, P
value
0.014 ,0.001 ,0.001 ,0.001 0.015 0.532 0.001 ,0.001 NA NA NA NA
Noncirrhotic
ALD vs
CTRL, P
value
,0.001 0.007 0.004 ,0.001 0.602 ,0.001 0.001 ,0.001 NA NA NA NA
CIR-HCV vs
CTRL, P
value
0.157 ,0.001 0.689 0.220 0.304 0.015 0.001 ,0.001 NA NA NA NA
CIR-NASH vs
noncirrhotic
NAFLD, P
value
0.624 ,0.001 0.173 ,0.001 0.149 0.020 0.013 ,0.001 NA NA NA NA
CIR-ALD vs
noncirrhotic
ALD, P value
0.624 ,0.001 0.001 ,0.001 0.101 ,0.001 1.000 0.241 NA 0.404 0.001 NA
CIR-HCV vs
noncirrhotic
HCV, P value
0.532 0.604 0.737 0.137 0.582 0.188 1.000 0.330 NA NA NA 0.425
Noncirrhotic
NAFLD vs
noncirrhotic
ALD, P value
,0.001 0.847 ,0.001 ,0.001 0.005 0.375 0.006 ,0.001 NA NA NA NA
Noncirrhotic
NAFLD vs
noncirrhotic
HCV, P value
0.187 ,0.001 ,0.001 0.009 0.361 0.066 0.033 0.004 NA NA NA NA
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4, http://links.lww.com/CTG/A153). We thus repeated the anal-
yses comparing BT-LAL of patients with at least one feature of
metabolic syndrome in the controls and in the NAFLD groups
separately, according to the PNPLA3 genotype. As shown in
Table 3, BT-LAL was significantly higher in the control group
compared with the NAFLD group when the IM (P5 0.017) and,
Table 1. (continued)
Men,
n (%) Age (yr)
BMI
(kg/m2)
Diabetes,
n (%)
Hypertension,
n (%)
Dyslipidemia,
n (%)
Statins,
n (%)
ALT
(UI/L)
MELD
score
Daily
alcohol
intake
(units)
Years of
at-risk
alcohol
intake
Years
since
HCV
infection
CIR-NASH vs
CIR-ALD, P
value
,0.001 ,0.001 0.019 0.001 0.009 0.009 1.000 0.220 0.327 NA NA NA
CIR-NASH vs
CIR-HCV, P
value
0.761 0.700 ,0.001 ,0.001 0.431 0.094 0.528 0.935 0.010 NA NA NA
Continuous variables are expressed asmedian (25th–75thpercentile), and the differences betweengroupswere evaluatedbyMann-WhitneyU test or t test according to the
variable normality. Categorical variables were expressed as count (percentages) and compared by the x2 test or Fisher exact test as appropriate.
ALD, alcoholic liver disease; ALT, alanine aminotransferase;BMI, bodymass index; CIR-ALD, patientswith alcoholic cirrhosis; CIR-HCV, patients withHCV-related cirrhosis;
CIR-NASH, patients with NASH-related cirrhosis; CTRL, controls with normal liver; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; NA, not applicable;
NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NC-HCV, noncirrhotic HCV, noncirrhotics with HCV-related liver disease; noncirrhotic ALD,
noncirrhotics with alcoholic liver disease; and noncirrhotic NAFLD, noncirrhotics with NAFLD.
Significant P values are reported in bold.
aAvailable in only 42 CIR-ALD patients.
Figure1.BT-LAL (a) platelet count (b) and leukocyte count and (c) in CTRL, in noncirrhotic ALD,CIR-ALD, noncirrhoticNAFLD, andCIR-NASH. *P,0.05;
**P, 0.01; ***P, 0.001. ALD, alcoholic liver disease; BT-LAL, blood total lysosomal acid lipase activity; CIR-ALD, cirrhotic patientswith ALD; CIR-NASH,
patients with NASH-related cirrhosis; CTRL, controls with normal liver; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; non-
cirrhotic ALD, noncirrhotics with ALD; and noncirrhotic NAFLD, noncirrhotics with NAFLD.
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evenmore,MM(P5 0.006) subjects were considered, whereas no
difference was present in the II subjects. No difference in the
platelet and leukocyte count was present, with the only exception
of lower leukocyte counts in the control subjects as compared to
the patients with noncirrhotic NAFLD when the PNPLA3 II
subjects were considered.
Table 2. Demographic, clinical, and biochemical characteristics of subjects with at least one feature of metabolic syndrome in the control
and noncirrhotic NAFLD groups
CTRL (n5 62) Noncirrhotic NAFLD (n 5 57) P value
BT-LAL nmol/spot/hr 0.88 (0.73–1.19) 0.76 (0.58–0.94) 0.005
Men, n (%) 29 (47) 31 (54) 0.407
Age (yr) 58 (51–72) 53 (44–60) 0.003
BMI (kg/m2) 25.6 (22.2–27.6) 28.9 (26.8–31.8) ,0.001
Diabetes, n (%) 6 (10) 18 (32) 0.003
Hypertension, n (%) 30 (48) 24 (42) 0.492
Dyslipidemia, n (%) 56 (90) 47 (83) 0.209
Statins, n (%) 26 (42) 14 (25) 0.45
ALT (UI/L) 17 (13–20) 48 (38–83) ,0.001
Platelet count (n 3 109/mL) 222 (184–263) 231 (186–231) 0.411
Leukocyte count (n3 103/mm3) 5.6 (4.9–6.5) 6.0 (5.5–7.2) 0.033
PNPLA3, n (%) ,0.001
II 22 (39) 26 (46)
IM 12 (21) 21 (37)
MM 22 (39) 10 (18)
Continuous variables are expressedasmedian (25th–75thpercentile), and thedifferences betweengroupswere evaluated byMann-WhitneyU test or t test according to the
variable normality. Categorical variables were expressed as count (percentages) and compared by the x2 tests.
ALT, alanine aminotransferase; BMI, body mass index; BT-LAL, blood total lysosomal acid lipase activity; CTRL, controls with normal liver; NAFLD, nonalcoholic fatty liver
disease; and noncirrhotic NAFLD, noncirrhotics with NAFLD.
Significant P values are reported in bold.
Table 3. Demographic, clinical, and biochemical characteristics of subjects with at least one feature of metabolic syndrome in the control
and noncirrhotic NAFLD groups, according to the PNPLA3 variant status
PNPLA3 II PNPLA3 IM PNPLA3 MM
CTRL NC-NAFLD P value CTRL NC-NAFLD P value CTRL NC-NAFLD
P
value
BT-LAL
(nanomoles/
spot/hr)
0.76 (0.64–1.07) 0.82 (0.65–1.10) 0.885 0.88 (0.73–1.40) 0.66 (0.51–0.89) 0.017 0.96 (0.78–1.13 0.68 (0.61–0.80) 0.006
Platelet count
(n 3 109/mL)
215 (188–286) 237 (200–282) 0.598 231 (210–278) 220 (179–257) 0.427 207 (171–236) 238 (183–270) 0.184
Leukocyte
count
(n3 103/mm3)
5.8 (4.3–6.3) 6.9 (5.7–7.7) 0.012 5.7 (5.3–7.4) 5.9 (5.0–6.7) 0.764 5.5 (4.8–6.4) 5.8 (5.3–7.0) 0.234
Male sex 13 (59) 13 (50) 0.529 4 (33) 12 (57) 0.282 11 (50) 6 (60) 0.712
Age (yr) 56 (47–71) 53 (45–64) 0.277 52 (37–71) 52 (33–60) 0.278 66 (55–75) 50 (45–54) 0.002
BMI 25.9 (23.1–27.5) 28.4 (26.7–30.7) 0.003 23.0 (20.0–26.5) 29.4 (27.4–32.9) ,0.001 26.1 (23.9–28.1) 28.5 (26.2–32.5) 0.082
ALT (UI/L) 17 (13–25) 47 (38–69) ,0.001 14 (12–21) 48 (33–96) ,0.001 16 (13–19) 81 (41–143) 0.006
Continuous variables are expressedasmedian (25th–75thpercentile), and thedifferences betweengroupswere evaluated byMann-WhitneyU test or t test according to the
variable normality. Categorical variables were expressed as count (percentages) and compared by the x2 tests.
ALT, alanine aminotransferase; BMI, body mass index; BT-LAL, blood total lysosomal acid lipase activity; CTRL, controls with normal liver; NAFLD, nonalcoholic fatty liver
disease; and NC-NAFLD, noncirrhotics with NAFLD.
Significant P values are reported in bold.
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BT-LAL in patients withNAFLD, alcoholic, andHCV liver disease
according to disease etiology and stage
We then separately investigated BT-LAL according to the stage of
chronic liver disease within the NAFLD and ALD groups. As
reported in Figure 1a, BT-LALwas significantly lower in alcoholic
cirrhosis as compared to patients with noncirrhotic ALD (P ,
0.001) and in NASH-related cirrhosis compared with non-
cirrhotic NAFLD (P , 0.001). Each cirrhotic group had signifi-
cantly lower platelet and leukocyte counts compared with the
respective noncirrhotic group (Figure 1b, c). After correction for
the significant intergroup differences shown in Table 1, at mul-
tivariable logistic regression analyses (Supplementary Table 3,
Supplementary Digital Content 5, http://links.lww.com/CTG/
A154), low BT-LAL was independently associated with the
presence of cirrhosis compared with the respective noncirrhotic
group of either nonalcoholic (OR0.059; 95%CI: 0.008–0.404;P5
0.004) or alcoholic (OR 0.080; 95% CI: 0.010–0.666; P 5 0.020)
etiology.
Finally, we compared BT-LAL according to the 2 different
etiologies, NAFLD and ALD, considering separately the non-
cirrhotic and the cirrhotic stage. Regarding the noncirrhotic
patients, as reported in Figure 1a, BT-LALwas significantly lower
in the NAFLD group compared with the ALD group (P, 0.001).
Platelet count did not differ between the noncirrhotic ALD and
NAFLD groups. Leukocyte count was significantly (P , 0.001)
lower in the noncirrhotic NAFLD group compared with the
noncirrhotic ALD group. After correction for the significant in-
tergroup differences shown in Table 1, at multivariable logistic
regression analyses (Supplementary Table 3, Supplementary
Digital Content 5, http://links.lww.com/CTG/A154), low total
blood LAL was independently associated with noncirrhotic
NAFLD compared with noncirrhotic ALD (OR 0.089; 95% CI:
0.017–0.452; P 5 0.004).
Regarding the cirrhotic patients, as reported in Figure 1a, BT-
LAL was significantly lower in the NASH-related group com-
pared with the alcoholic group (P , 0.05). No intergroup dif-
ference was found regarding platelet and leukocyte counts. After
correction for the significant intergroup differences shown in
Table 1, at multivariable logistic regression analyses (Supple-
mentary Table 3, Supplementary Digital Content 5, http://links.
lww.com/CTG/A154), low BT-LAL was independently associ-
ated with NASH-related compared with alcoholic cirrhosis (OR
0.174; 95% CI: 0.033–0.923; P5 0.013).
Similar to ALD, BT-LAL was significantly lower in patients
with HCV-related cirrhosis compared with both the controls and
the noncirrhotic HCV group, whereas it did not differ between
the noncirrhotic HCV group and controls (Supplemental results
and Figure 1, Supplementary Digital Content 1, http://links.lww.
com/CTG/A150).
Intracellular LAL in platelets and leukocytes according to the
NAFLD stage
Because we found that BT-LAL compared with that in controls
with normal liverwas progressively reduced inNAFLDaccording
to the disease stage, we then investigated LAL at the intracellular
level of platelets and leukocytes isolated from control subjects
(n 5 14), noncirrhotic NAFLD (n 5 14), and NASH-related
cirrhotics (n 5 14) (Supplementary Table 4, Supplementary
Digital Content 6, http://links.lww.com/CTG/A155). Both leu-
kocyte and platelet isolation procedures yielded high purity
preparations (Supplementary Figure 2, Supplementary Digital
Content 2, http://links.lww.com/CTG/A151).
Intracellular platelet activity normalized by cellular total
protein content was significantly reduced in patients with non-
cirrhotic NAFLD (175 [108–270] nmol/mg of protein/hr; P 5
0.022) and evenmore in patients withNASH-related cirrhosis (84
[51–177] nmol/mg of protein/hr; P, 0.001) compared with that
in control subjects (314 [214–416] nmol/mg of protein/hr)
(Figure 2a). Interestingly, intracellular platelet LAL was also
significantly reduced in NASH-related cirrhosis compared with
patients with noncirrhotic NAFLD (P 5 0.022). At difference,
intracellular leukocyte LAL did not differ among the 3 groups
(Figure 2b), being 211 (123–290) nmol/mg of protein/hr in
Figure 2. Intracellular platelet (a) and leukocyte (b) LAL in CTRL,
noncirrhotic NAFLD, and CIR-NASH. *P , 0.05. CIR-NASH, patients
with NASH-related cirrhosis; CTRL, controls with normal liver; LAL,
lysosomal acid lipase activity; NAFLD, nonalcoholic fatty liver disease;
NASH, nonalcoholic steatohepatitis; and noncirrhotic NAFLD, noncir-
rhotics with NAFLD.
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preparations (Supplementary Figure 2, Supplementary Digital
Content 2, http://links.lww.com/CTG/A151).
Intracellular platelet activity normalized by cellular total
protein content was significantly reduced in patients with non-
cirrhotic NAFLD (175 [108–270] nmol/mg of protein/hr; P 5
0.022) and evenmore in patients withNASH-related cirrhosis (84
[51–177] nmol/mg of protein/hr; P, 0.001) compared with that
in control subjects (314 [214–416] nmol/mg of protein/hr)
(Figure 2a). Interestingly, intracellular platelet LAL was also
significantly reduced in NASH-related cirrhosis compared with
patients with noncirrhotic NAFLD (P 5 0.022). At difference,
intracellular leukocyte LAL did not differ among the 3 groups
(Figure 2b), being 211 (123–290) nmol/mg of protein/hr in
controls, 126 (95–291) nmol/mg of protein/hr in noncirrhotic
NAFLD, and 169 (109–215) nmol/mg of protein/hr in patients
with NASH-related cirrhosis.
BT-LAL after LT and de novo graft NAFLD
We then investigated BT-LAL according to the evidence at
ultrasounds of post-transplant de novo graft NAFLD in stable
patients who had undergone LT. As shown in Figure 3a, BT-LAL
was significantly lower (P 5 0.034) in recipients with post-
transplant NAFLD (0.51 [0.43–0.72] nmol/spot/hr) than in those
without NAFLD (0.69 [0.51–0.96] nmol/spot/hr), whereas no
intergroup difference was found regarding platelet (Figure 3b)
and leukocyte (Figure 3c) counts, any metabolic syndrome fea-
ture, statin treatment, and time since LT (Supplementary Table 5,
Supplementary Digital Content 7, http://links.lww.com/CTG/
A156).
We finally investigated whether the reduced BT-LAL levels
that we found in nontransplanted cirrhosis changes after LT.
Thus, we compared BT-LAL of our patients with NASH-related
(n5 51) and alcoholic (n5 63) cirrhosiswith that of patientswho
underwent stable liver transplantation whose indication for LT
had been either NASH-related (n 5 26) or alcoholic (n 5 20)
cirrhosis. The median distance from operation of the trans-
planted patients was 4.6 years. As shown in Figure 4a, BT-LALdid
not differ before and after LT for NASH-related cirrhosis (0.48
[0.39–0.69] nmol/spot/hr vs 0.52 [0.44–0.75] nmol/spot/hr, re-
spectively) and for alcoholic cirrhosis (0.63 [0.46–0.89] nmol/
spot/hr vs 0.73 [0.49–0.94] nmol/spot/hr, respectively). However,
transplanted compared with nontransplanted cirrhotic patients
had significantly higher platelet (Figure 4b) and leukocyte
(Figure 4c) counts. Eight of these patients were studied both be-
fore and after LT. BT-LAL (0.50 6 0.15 nmol/spot/hr vs 0.56 6
0.33 nmol/spot/hr, respectively) and leukocyte count (4.896 1.31
vs 5.656 1.21 [n3103/mm3], respectively) did not differ before
and after LT. However, platelet count was significantly (P 5
0.012) higher after than before LT (134.0 6 36.5 vs 48.9 6 17.7
[n 3 109/mL], respectively).
DISCUSSION
The main findings of our present study are as follows: (i) a pro-
gressive reduction of BT-LAL according to chronic liver disease
stage, peculiar to nonalcoholic fatty liver disease (NAFLD) and
independent from confounders; (ii) a progressive reduction of
intracellular LAL in circulating platelets, but not in leukocytes, of
patients with nonalcoholic fatty liver whichwas dependent on the
disease stage and paralleled enzymatic activity reduction inwhole
blood; (iii) normal BT-LAL levels in heavy drinkers and in HCV
infected subjects without evidence of cirrhosis; (iv) progressively
high BT-LAL in PNPLA3 allele M carriers (IM and MM) with
some of the metabolic syndrome features but without steatosis;
and (v) significantly lower BT-LAL in LT recipients with post-
Figure 3. BT-LAL (a), platelet count (b) and leukocyte count (c) in liver
transplant recipients with (NAFLD) and without (NO-NAFLD) de novo
NAFLD. *P, 0.05. BT-LAL, blood total lysosomal acid lipase activity; and
NAFLD, nonalcoholic fatty liver disease.
Clinical and Translational Gastroenterology VOLUME 11 | FEBRUARY 2020 www.clintranslgastro.com
LI
VE
R
Ferri et al.8
transplant de novo NAFLD compared with those without
NAFLD.
We first investigated BT-LAL in patients at both the non-
cirrhotic and cirrhotic stages of 3 chronic liver diseases selected to
obtain groups with a single pure etiology, namely, NAFLD, al-
coholic fatty liver disease, and HCV. We found that low BT-LAL
was independently associated with the cirrhotic stage of each of
the 3 different etiologies of chronic liver disease compared with
controls. However, we found that only in NAFLD, there is a pe-
culiar progressive reduction of BT-LAL, according to disease
severity that also involves the noncirrhotic stage. Reduced BT-
LAL in NAFLD could, in theory, be simply explained by the low
number of platelets present in cirrhosis and reported also to occur
in the precirrhotic stage of the disease (3,13). However, we found
that low BT-LAL was independently associated with NASH-
related cirrhosis compared with alcoholic cirrhosis, with non-
cirrhotic NAFLD compared with controls and noncirrhotic ALD
and, in the post-transplant setting, with de novo NAFLD com-
pared with the absence of steatosis, even if platelets did not differ
for each comparison.
In addition, wemeasured for the first time intracellular LAL in
circulating cells of patients with different stages of NAFLD and
controls with normal liver. Thus, we provided direct evidence for
a progressively reduced LAL, expressed per mg of intracellular
protein, carried by platelets, but not of that carried by leukocytes,
in noncirrhotic NAFLD and, in a more severe fashion, in NASH-
related cirrhosis. In particular, LAL carried by platelets in cir-
rhotic and noncirrhotic patients was 56% and 27% of that present
in controls, respectively.
Our present demonstration of a progressively reduced BT-LAL
according to the disease severity only in NAFLD, paralleled by
a reduction of LAL in platelets, and the association of reduced BT-
LAL with post-transplant de novo NAFLD strongly suggest that
low LAL is peculiar toNAFLD, probably because of transcriptional
or post-transcriptional reductions of LAL in platelets (7,10,24).
On the other hand, our data show that having normal BT-LAL
values is associated with protection fromNAFLDdevelopment in
subjects with features ofmetabolic syndrome. In fact, normal BT-
LAL was associated with the absence of steatosis even in subjects
withmetabolic syndrome features that should have been prone to
the development of steatosis as carriers of the PNPLA3 variant
that was found to be strongly associated with fat accumulation in
hepatocytes (18). It should be noted that, in our study, BT-LAL
was progressively increased in PNPLA3 variant II, IM, and MM
subjects with features of metabolic syndrome but without stea-
tosis, suggesting a protective role of high LAL in the sense that the
more the genetic factor is unfavorable, the higher the BT-LAL
values must be to protect against the development of NAFLD.
The concept that circulating cells with reduced LAL can in-
duce NAFLD is in keeping with the well-described recurrence of
liver steatosis and cirrhosis after LT in patients with LAL de-
ficiency (6). To explain post-transplant liver disease recurrence in
patients with LAL deficiency, it has been hypothesized that in-
sufficient lipophagy in Kupffer cells and in bone marrow-derived
myeloid cells would lead to their immunometabolic activation
and migration into the liver with inflammation (1,6,25–27). We
hypothesized that the reduced platelet LAL that we found in
NAFLD causes subnormal lipophagy, cholesterol accumulation,
and their metabolic activation (28–30). This metabolic activation
Figure 4.BT-LAL (a), platelet count (b) and leukocyte count (c) in CIR-
ALD, CIR-NASH, and in OLT-ALD and OLT-NASH cirrhosis. **P ,
0.01; ***P , 0.001. ALD, alcoholic liver disease; BT-LAL, blood total
lysosomal acid lipase activity; CIR-ALD, nontransplanted cirrhotic
patients with ALD; CIR-NASH, nontransplanted patients with NASH-
related cirrhosis; NASH, nonalcoholic steatohepatitis; OLT-ALD,
transplanted patients with pretransplant alcohol-related cirrhosis;
and OLT-NASH, transplanted patients with pretransplant NASH-
related cirrhosis.
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of platelets could increase their migration into the space of Disse
and their demonstrated inflammatory capacity, as recently shown
by Malehmir et al. (9). In addition, the involvement of platelet
activation in NAFLD pathogenesis is reinforced by the beneficial
effects of antiplatelet therapy that have been reported in animal
models and in patients with NAFLD (9,31–33). Further studies
will be needed to correlate LAL and lipidome in platelets and their
migration and activation into the liver. These studies will unravel
the mechanisms underlying the reduction of LAL in platelets of
patients with nonalcoholic fatty liver and its physiopathological
role. A further unresolved question raised by our results is why
BT-LAL levels of cirrhotic patients are similar before and after LT,
although platelet and leukocyte counts increase after operation. A
possible explanation could be that because LAL is inducibile by
fasting/starving (34), the opposite occurs after LT when calorie
intake increases compared with that before operation with the
reduction of LAL. In keepingwith this hypothesis, it is known that
LAL is induced by a low calorie intake (35).
A limitation of our study is that data on intracellular LAL have
been obtained from a small number of patients. In addition, re-
garding the intergroupdifferences of BT-LAL, our study is limited
by its monocentric and cross-sectional design and needs confir-
mation in larger studies because groups are relatively small. On
the other hand, our study groups, including those with NAFLD,
were carefully characterized for disease stage and unique etiology,
avoiding the overlapping of liver disease cofactors, and we se-
lected patients with a diagnosis of NASH-related cirrhosis and
not those with cryptogenic cirrhosis (14–17).
Finally, our study was not designed to relate BT-LAL to his-
tological NAFLD features and future prospective studies in-
volving repeated liver biopsies of patients with NAFLD are
needed to definitely unravel the strength of the association be-
tween reduced BT-LAL and disease severity. Studies involving
a larger number of patients could also ascertain whether mea-
surement of BT-LAL in patients with nonalcoholic fatty acid liver
disease could be useful as a new noninvasive marker of liver
disease severity across its different fibrosis stages.
Our results could also have possible implications for non-
alcoholic fatty acid liver disease treatment, even if improving the
LAL levels could result in a reduction of hepatic fat and/or in-
flammation in these patients is still unclear (35,36).
In conclusion, our data show that reduced LAL is associated
with NAFLD because LAL, both in blood and in platelets, is
progressively reduced according to disease stage. LAL reduction
in blood at the noncirrhotic stage is unique for NAFLD and not
for other etiologies of liver damage and is also associated with de
novo post liver transplant NAFLD. In addition, normal LAL in
blood is associated with the absence of steatosis even in subjects
withmetabolic syndrome features andLAL in bloodprogressively
increases in PNPLA3 steatosis associated variant II, IM, andMM
subjects without liver disease, suggesting that high LAL can be
protective and low LAL detrimental for NAFLD development.
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